Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

28.76 USD UNCHANGED
Streaming Delayed Price Updated: 5:28 AM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Myriad Genetics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care 
From GlobeNewswire News Releases
Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan
From GlobeNewswire News Releases
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives
New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal 
From GlobeNewswire News Releases
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021
From GlobeNewswire News Releases
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those who can... 
From GlobeNewswire News Releases
Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences
From GlobeNewswire News Releases
GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels
From GlobeNewswire News Releases
Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
From GlobeNewswire News Releases
Myriad Genetics, Inc. (NASDAQ:MYGN) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 01/25/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Myriad Genetics, Inc. 
From SBWire - Latest Press Releases
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of... 
From PR Newswire
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
From GlobeNewswire News Releases
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Focus on Women’s Health, Oncology, Mental Health to Improve Execution and Accelerate Growth 
From GlobeNewswire News Releases
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
From GlobeNewswire News Releases
IPM Launches Innovative Program for Rheumatoid Arthritis
Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and... 
From PR Newswire
Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression
New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” 
From GlobeNewswire News Releases
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
From GlobeNewswire News Releases
Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China
From GlobeNewswire News Releases
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
From GlobeNewswire News Releases
Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
From GlobeNewswire News Releases
Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020
From GlobeNewswire News Releases
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests
From GlobeNewswire News Releases
Myriad Genetics and Sandstone Diagnostics Form Point-of-Care Blood Collection Partnership
Tags s:california science c:united/kingdom
From EIN Presswire
Myriad Genetics Expands Board of Directors with New Member
Rashmi Kumar Elected to Myriad’s Board of Directors 
From GlobeNewswire News Releases
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
From GlobeNewswire News Releases
Myriad Genetics Announces Inducement Awards
From GlobeNewswire News Releases
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors
From GlobeNewswire News Releases
Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results
From GlobeNewswire News Releases
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
From GlobeNewswire News Releases
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.